期刊文献+

重组人甲状旁腺激素1-34对骨质疏松性骨折愈合影响的实验研究 被引量:3

Effects of recombinant human parathyroid 1-34 on healing of osteoporotic fractures
原文传递
导出
摘要 目的研究重组人甲状旁腺激素1-34(rhPTH1-34)片段对大鼠骨质疏松性骨折愈合的影响。方法选择6个月龄雌性SD大鼠80只,随机分为rhPTH1-34组、雌激素组、对照组(骨质疏松组)及假手术组,每组20只。前三组切除双侧卵巢,假手术组暴露卵巢而不切除,术后3个月行右侧股骨中段骨折内固定术。术后分别皮下注射rhPTH1-34、苯甲酸雌二醇及等量生理盐水,进行骨密度、X线片组织病理学和生物力学检测,观察骨折愈合情况。结果rhPTH1-34组骨折局部骨密度明显高于对照组,差异有统计学意义(P〈0.05);rhPTH1-34组比同时期的对照组骨痂生成量多,愈合时间提前。结论rhPTH1-34能促进骨形成,增加骨量,加快骨痂形成,促进骨质疏松性骨折愈合,同时能提高骨生物力学特性和抗骨折能力。 Objective To research the effects of recombinant human parathyroid 1-34 (rhPTH1-34) on healing of osteoporotic fractures in rats. Methods Eighty female SD rats of 6 months old were randomly divided into 4 equal groups: rhPTH1-34 group, estrogen group, osteoporosis group (control) and sham-operation group. Internal fixation of fractures of right mid femur was performed for the former 3 groups 3 months after bilateral ovariectomy. Subcutaneous injections of rhPTH1-34, oestradiol benzoate and physiologic saline were conducted respectively after fixation. BMD, X-ray, histopathological analysis of callus and biomechanicaltests were used to evaluate the bone healing. Results The BMD and biomechanical property in the rhPTH1-34 group were significantly superior to those in the other 3 groups 9 weeks after treatment ( P 〈 0.05) . Conclusion rhPTH1-34 can stimulate the growth of bone, increase the BMD, and promote the fracture healing in ovariectomized rats.
出处 《中华创伤骨科杂志》 CAS CSCD 2007年第5期448-451,共4页 Chinese Journal of Orthopaedic Trauma
关键词 受体 甲状旁腺激素 骨质疏松 骨折 Receptors, parathyroid hormone Osteoporosis Fracture
  • 相关文献

参考文献12

  • 1罗先正,郭艾,王宝军.骨质疏松症与脊柱骨折[J].中华创伤骨科杂志,2004,6(2):121-124. 被引量:36
  • 2Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med, 2001, 344: 1434-1441.
  • 3王洪复,金慰芳,高建军,顾淑珠,周轶,孙爱龙,胡菲,沈洁,张顺昌.重组人甲状旁腺激素_(1-34)对去卵巢大鼠骨质疏松的治疗作用[J].中国医学科学院学报,2003,25(3):275-279. 被引量:25
  • 4Locklin RM, Khosla S, Turner RT, et al. Mediators of the biphasic responses of bone to intermittent and continuously administered parathyroid hormone. J Cell Biochem, 2003, 89: 180-190.
  • 5Kneissel M, Boyde A, Gasser JA. Bone tissue and its mineralization in aged estrogen-depleted rats after long-term intermittent treatment with parathyroid hormone (PTH) analog SDZ PTS 893 or human PTH (1-34). Bone, 2001, 28: 237-250.
  • 6Thomsen JS, Mosekilde LI, Gasser JA. Long-term therapy of ovariectomy-induced osteopenia with parathyroid hormone analog SDZ PTS 893 and bone maintenance in trtired breeder rats. Bone, 1999, 25: 561-569.
  • 7Hirano T, Burr DB, Turner CH, et al. Anabolic effects of human biosynthetic parathyroid hormone fragment(I-34), LY333334, on remodeling and mechanical properties of cortical bone in rabbits. J Bone Miner Res, 1999, 14: 536-545.
  • 8Rossouw JE, Anderson GL, Prentice RL, et al. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA, 2002, 288:321-333.
  • 9Vahle JL, Sato M, Long GG, et al. Skeletal changes in rats given daily subcutaneous injections of recombinant human parathyroid hormone (1-34) for 2 years and relevance to human safety. Toxicol Pathol, 2002, 30: 312-321.
  • 10Orwoll ES, Scheele WH, Paul S, et al. The effect of teriparatide [human parathyroid hormone (1-34)] therapy on bone density in men with osteoporosis. J Bone Miner Res, 2003, 18: 9-17.

二级参考文献12

  • 1李晨,吴志福,林国栋.老年骨质疏松性腰背痛误诊调查[J].颈腰痛杂志,1997,18(2):91-92. 被引量:7
  • 2Silverberg SJ, Shane E, de la Cruz L, et al. Skeletal disease in Primary hyperparathyroidism. J Bone Miner Res,1989, 4:281-291.
  • 3Rubin Mr, Cosman F, Lindsay IL et al. The anabolic effects of parathyroid hormone. Osteoporos Int, 2002, 13:267-277.
  • 4Ejersed C, Andeassen TF, Hauge EM, et al. Parathyroid bormone(1-34) increases vertebral bone mass, compressive strength, and quality in old rats. Bone, 1995, 17(6):507-511.
  • 5Sato M, Vahle J, Schmidt A, et al. Abnormal bone architecture and biomechanical properties with near-lifetime treatment of rats with PTH. Endocrinology, 2002, 143:3230-3242.
  • 6Okimoto N, Tsurukami H, Okazaki Y, et al. Effects of a weekly injection of human parathyroid hormone(1-34) and withdrawal on bone mass, stxength, and tumover in mature ovariectomized rats. Bone, 1998, 22:523-531.
  • 7Brommage R, Hotchkiss CE, Lces CJ, et al. Daily treatment with human recombinant parathyroid hormone(1-34) LY333334,for l year increases bone mass in ovariectomized monkeys.J Clin Endocrinol Metab, 1999. 84(10):3757-3763.
  • 8Sato M, Weatmore M, Clendenon J, et al. Three-dimensional modeling of the effects of parathyroid hormone on bone distribution in lumber vertebrate of ovariectomized cynomolgus macaques. Osteoporm lnt, 2000, 11(10):871-880.
  • 9Ma YL, Cain RI, Helladay DL, et al. Catabolic effects of continuous human PTH (1-38) in vivo is associated with sustained stimulation of RANKL and inhibition of osteoprotegerin and gene-associated bone formation. Endocrinology,2001, 142:4047-4054.
  • 10Locklin RM, Khosla S, Riggs BL. Mechanism of biphasic and catabolic effects of parathyroid hormone(PTH) on bone cells. Bone, 2001, 28 (Suppl):580.

共引文献59

同被引文献26

  • 1金慰芳,于志锋,高建军,顾淑珠,周轶,王洪复.PTH对骨髓细胞骨代谢相关基因表达的影响[J].中国骨质疏松杂志,2005,11(3):286-288. 被引量:11
  • 2Silverberg SJ, Shane E, de la Cruz L, et al. Skeletal disease in Primary hyperparathyroidism[J]. J Bone Miner Res, 1989,4 (3) : 283-291.
  • 3Elaena Q, Helen K. Teriparaticte: a review[J]. Clinic Treat, 2004,26(6) :841-854.
  • 4Anastasilakis AD, Goulis DG, Polyzos SA, et al. Head-to-head comparison of risedronate vs teriparatide on bone turnover markers in women with postmenopausal osteoporosis: a randomized trial[J]. Int J Clin Pract, 2008, 62(6) : 919-924.
  • 5Lewiecki EM. Current and emerging pharmacologic therapies for the management of postmenopausal osteoporosis[J]. J Women's Health, 2009, 18(10):1615- 1626.
  • 6Verhaar HJJ, Lems WF. PTH -analogs: comparable or different [J]? Arch Geront Geriatr, 2009 (49) : 130- 132.
  • 7Vahle JL, Sato M, Long G G, et al. Skeletal changes in rats given daily subcutaneous injections of recombinant human parathyroid hormone (1- 34) for 2 years and relevance to human safety[J]. Toxicol Pathol, 2002, 30(3): 312-321.
  • 8Carbone LD, Tylavsky FA, Cauley JA, et al. Association between bone mineral density and the use of nonsteroidal anti- inflammatory drugs and 'aspirin: impact of cyclooxygenase selectivity[J].Bone Miner Res,2003,18(10):1795-1802.
  • 9Bauer DC, Orwoll ES, Fox KM, et al. Aspirin and NSAID use inolder women.- effect on bone mineral density and fracture risk. Study of Osteoporotic Fractures Research Group[J].Bone Miner Res, 1995,11 (1): 29-35.
  • 10Yamaza T, Miura Y, Bi Y, et al. Pharmacologic stem cell based Intervention as a new apl~roach to osteoporosis treatment in rodents[J].PLoS ONE,2008,3(7) :2615-2624.

引证文献3

二级引证文献17

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部